194 related articles for article (PubMed ID: 16467106)
1. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications.
Chen B; Pogue BW; Luna JM; Hardman RL; Hoopes PJ; Hasan T
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):917-23. PubMed ID: 16467106
[TBL] [Abstract][Full Text] [Related]
2. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model.
Chen B; Pogue BW; Zhou X; O'Hara JA; Solban N; Demidenko E; Hoopes PJ; Hasan T
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):720-7. PubMed ID: 15701861
[TBL] [Abstract][Full Text] [Related]
3. Disparity between prostate tumor interior versus peripheral vasculature in response to verteporfin-mediated vascular-targeting therapy.
Chen B; Crane C; He C; Gondek D; Agharkar P; Savellano MD; Hoopes PJ; Pogue BW
Int J Cancer; 2008 Aug; 123(3):695-701. PubMed ID: 18498134
[TBL] [Abstract][Full Text] [Related]
4. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy.
Chen B; Pogue BW; Hoopes PJ; Hasan T
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1216-26. PubMed ID: 15752904
[TBL] [Abstract][Full Text] [Related]
5. Intravital microscopic analysis of vascular perfusion and macromolecule extravasation after photodynamic vascular targeting therapy.
He C; Agharkar P; Chen B
Pharm Res; 2008 Aug; 25(8):1873-80. PubMed ID: 18446275
[TBL] [Abstract][Full Text] [Related]
6. Comparison between endothelial and tumor cells in the response to verteporfin-photodynamic therapy and a PI3K pathway inhibitor.
Fateye B; Wan A; Yang X; Myers K; Chen B
Photodiagnosis Photodyn Ther; 2015 Mar; 12(1):19-26. PubMed ID: 25636781
[TBL] [Abstract][Full Text] [Related]
7. Leukocyte-endothelial cell interaction is necessary for photodynamic therapy induced vascular permeabilization.
Debefve E; Mithieux F; Perentes JY; Wang Y; Cheng C; Schaefer SC; Ruffieux C; Ballini JP; Gonzalez M; van den Bergh H; Ris HB; Lehr HA; Krueger T
Lasers Surg Med; 2011 Sep; 43(7):696-704. PubMed ID: 22057497
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic enhancement of vascular-targeted photodynamic therapy by inhibiting proteasomal function.
Li Z; Agharkar P; Chen B
Cancer Lett; 2013 Oct; 339(1):128-34. PubMed ID: 23872275
[TBL] [Abstract][Full Text] [Related]
9. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells.
Tirand L; Frochot C; Vanderesse R; Thomas N; Trinquet E; Pinel S; Viriot ML; Guillemin F; Barberi-Heyob M
J Control Release; 2006 Mar; 111(1-2):153-64. PubMed ID: 16423422
[TBL] [Abstract][Full Text] [Related]
10. Peptide-induced inflammatory increase in vascular permeability improves photosensitizer delivery and intersubject photodynamic treatment efficacy.
Zhou X; Chen B; Hoopes PJ; Hasan T; Pogue BW
Radiat Res; 2007 Sep; 168(3):299-307. PubMed ID: 17705632
[TBL] [Abstract][Full Text] [Related]
11. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
Wong Kee Song LM; Wang KK; Zinsmeister AR
Cancer; 1998 Jan; 82(2):421-7. PubMed ID: 9445202
[TBL] [Abstract][Full Text] [Related]
12. Neuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release.
Bechet D; Tirand L; Faivre B; Plénat F; Bonnet C; Bastogne T; Frochot C; Guillemin F; Barberi-Heyob M
Pharm Res; 2010 Mar; 27(3):468-79. PubMed ID: 20087632
[TBL] [Abstract][Full Text] [Related]
13. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.
Renno RZ; Terada Y; Haddadin MJ; Michaud NA; Gragoudas ES; Miller JW
Arch Ophthalmol; 2004 Jul; 122(7):1002-11. PubMed ID: 15249365
[TBL] [Abstract][Full Text] [Related]
14. Investigation of cell death mechanisms in human lymphatic endothelial cells undergoing photodynamic therapy.
Wachowska M; Osiak A; Muchowicz A; Gabrysiak M; Domagała A; Kilarski WW; Golab J
Photodiagnosis Photodyn Ther; 2016 Jun; 14():57-65. PubMed ID: 26868051
[TBL] [Abstract][Full Text] [Related]
15. Analysis of effective molecular diffusion rates for verteporfin in subcutaneous versus orthotopic Dunning prostate tumors.
Zhou X; Pogue BW; Chen B; Hasan T
Photochem Photobiol; 2004 Apr; 79(4):323-31. PubMed ID: 15137508
[TBL] [Abstract][Full Text] [Related]
16. Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer.
Takeuchi Y; Kurohane K; Ichikawa K; Yonezawa S; Nango M; Oku N
Cancer; 2003 Apr; 97(8):2027-34. PubMed ID: 12673734
[TBL] [Abstract][Full Text] [Related]
17. Tumor-secreted vascular permeability factor/vascular endothelial growth factor influences photosensitizer uptake.
Roberts WG; Hasan T
Cancer Res; 1993 Jan; 53(1):153-7. PubMed ID: 8416739
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic drug delivery enhancement in tumours does not depend on leukocyte-endothelial interaction in a human mesothelioma xenograft model.
Wang Y; Perentes JY; Schäfer SC; Gonzalez M; Debefve E; Lehr HA; van den Bergh H; Krueger T
Eur J Cardiothorac Surg; 2012 Aug; 42(2):348-54. PubMed ID: 22290897
[TBL] [Abstract][Full Text] [Related]
19. Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy.
Grisanti S; Tatar O; Canbek S; Lafaut BA; Gelisken F; Inhoffen W; Szurman P; Aisenbrey S; Oficjalska-Mlynczak J; Bartz-Schmidt KU
Am J Ophthalmol; 2004 May; 137(5):914-23. PubMed ID: 15126158
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment photosensitizer dosimetry reduces variation in tumor response.
Zhou X; Pogue BW; Chen B; Demidenko E; Joshi R; Hoopes J; Hasan T
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1211-20. PubMed ID: 16504761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
